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ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA 
The relation between serum vitamin D levels and clinical findings of fibromyalgia 
syndrome
Serum vitamin D seviyelerinin fibromiyalji sendromunun klinik bulguları ile ilişkisi
Nurcan Kılıç Baygutalp1, Fatih Baygutalp2, Buminhan Şeferoğlu2, Ebubekir Bakan1
ÖZET
Amaç: Bu çalışma, fibromiyalji sendromlu (FMS) hasta-
larda serum 25-OH vitamin D seviyelerini belirlemek ve 
25-OH vitamin D seviyelerinin klinik bulgular ile ilişkisini 
araştırmak amacıyla yapıldı. 
Yöntemler: Çalışmaya ACR 1990 fibromiyalji tanı kriter-
lerine  göre  tanı  konulan  ondokuz  premenapozal  kadın 
ve kontrol grubu olarak 24 premenapozal sağlıklı kadın 
dahil edildi. Yaygın vücut ağrısı, baş ağrısı, yorgunluk, 
sabah tutukluğu, uyku bozukluğu, hassas nokta sayısı, 
fibromiyalji etki anketi skorları ve Beck depresyon skorları 
FMS’nin klinik bulguları olarak değerlendirildi. 
Bulgular: Serum 25-OH vitamin D seviyeleri FMS’li has-
talarda kontrol grubuna göre anlamlı olarak daha düşük-
tü (p=0.01). FMS grubunda 25-OH vitamin D seviyeleri 
ile yaygın vücut ağrısı (r=-0.731), Beck depresyon skor-
ları (r=-0.777), baş ağrısı (r=-0.629) ve uyku bozukluğu 
arasında  (r=-0.767)  anlamlı  negatif  korelasyonlar  vardı 
(p<0.01).
Sonuç: 25-OH vitamin D eksikliğinin FMS’nin yaygın vü-
cut ağrısı, depresyon, baş ağrısı ve uyku bozukluğu gibi 
klinik bulguları ile ilişkili olabileceği değerlendirildi. 
Anahtar kelimeler: Fibromiyalji, klinik bulgu, 25-OH vi-
tamin D
ABSTRACT
Objective: This study was performed to identify serum 
25-OH vitamin D levels and to investigate the relationship 
between 25-OH vitamin D and clinical findings on patients 
with fibromyalgia syndrome (FMS).
Methods:  Nineteen  premenopausal  women  with  FMS 
who were diagnosed according to ACR 1990 fibromyalgia 
diagnostic criteria and 24 premenopausal healthy women 
as control group were included in the study. Serum 25-OH 
vitamin D levels were determined in both patient and con-
trol groups. Widespread body pain, headache, fatigue, 
morning stiffness, sleep disorder, the number of tender 
points, Fibromyalgia Impact Questionnaire (FIQ) scores 
and Beck depression scores were evaluated as clinical 
findings in patients with FMS.
Results:  Serum  25-OH  vitamin  D  levels  were  signifi-
cantly lower in patients with FMS than those in control 
group (p=0.01). There were significantly negative corre-
lations between 25-OH vitamin D levels and widespread 
body pain (r=-0.731), Beck depression scores (r=-0.777), 
headache (r=-0.629), and sleep disorder (r=-0.767) in the 
FMS group (p<0.01).
Conclusion: It was concluded that 25-OH vitamin D de-
ficiency may be related to the clinical findings such as 
widespread body pain, depression, headache and sleep 
disorder in patients with FMS.
Key words: Fibromyalgia, clinical finding, 25-OH vitamin 
D 
INTRODUCTION
Fibromyalgia  syndrome  (FMS)  is  a  chronic  pain 
syndrome causing widespread body pain, stiffness, 
and tenderness points on specific anatomic regions. 
It is also characterized by restless sleep, tiredness, 
fatigue,  anxiety,  depression,  and  disturbances  in 
bowel functions [1,2].
The etiopathogenesis of fibromyalgia syndrome 
(FMS) remains unknown. The interactions of neuro-
endocrine, metabolic and immunological factors are 
assumed to play role in the induction and mainte-N. K. Baygutalp et al. Serum vitamin D levels and clinical findings of fibromyalgia 447
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nance of FMS [3,4]. Neuroendocrine mechanisms, 
various hormones, serotonin, melatonin, substance 
P, endorphins, and vitamin D levels were researched 
on until now with respect to the etiopathogenesis of 
FMS [5-9].
The relationship between low levels of 25-OH 
vitamin D and non-specific skeletal-muscular pains 
including FMS is controversial. While a positive 
correlation was found between vitamin D levels and 
FMS in many studies, no relationship was found in 
others.
The aim of this study is to determine serum 25-
OH vitamin D levels in patients with FMS and the 
control group of healthy individuals. Additionally, 
the correlations between 25-OH vitamin D levels 
and some of the clinical findings of FMS - wide-
spread body pain, headache, fatigue, morning stiff-
ness, sleep disorder, the number of tender points, 
Fibromyalgia Impact Questionnaire (FIQ) and Beck 
depression scores - were evaluated.
METHODS
Nineteen premenopausal women (aged 27-47 years, 
average 36.35±7.04 years) who were admitted to 
our outpatient clinic between 1 July - 30 August 
2011 and met the 1990 American College of Rheu-
matology (ACR) criteria for the diagnosis of FMS 
were enrolled in the study. The control group was 
composed of twenty-four age and location matched 
healthy  premenopausal  women  who  had  normal 
physical examination and routine test results and 
had no chronic and endocrinological diseases. 25-
OH vitamin D levels were determined in FMS pa-
tients and controls.
Widespread  body  pain,  headache,  fatigue, 
morning  stiffness,  sleep  disorder,  the  number  of 
tender points, Fibromyalgia Impact Questionnaire 
(FIQ) and Beck depression scores were evaluated 
as clinical findings in patients. Fibromyalgia Impact 
Questionnaire (FIQ) was evaluated by Turkish ver-
sion [10] of original FIQ [11]. The number of ten-
der points was determined by ACR 1990 diagnostic 
criteria [12]. Depression scores were evaluated by 
Turkish version [13] of original Beck Depression 
Scale [14]. Widespread pain and fatigue were mea-
sured with 10-cm visual analog (VAS) scale [15]. 
Morning stiffness was evaluated by morning stiff-
ness  scale  of  Lequesne  index  (as  0=no  stiffness, 
1=low  stiffness-less  than  15  minutes,  2=severe 
stiffness-more than 15 minutes) [16]. 
Sleep  disorder  was  evaluated  sleep  latency 
component of Pittsburgh Sleep Quality Index (as 
0= no difficulty or difficulty falling asleep for ≤ 15 
minutes, 1=difficulty falling asleep for 16-30 min-
utes, 2=difficulty falling asleep for 31-60 minutes, 
3=difficulty falling asleep for more than 60 min-
utes) [17]. Headache was evaluated by 4 definitive 
words  of  Short-Form  McGill  Pain  Questionnaire 
used to determine the affective dimensions of pain 
(as 0=no headache, 1=low headache, 2=mild head-
ache, 3=severe headache) [18].
Since neuroendocrine abnormalities have role 
in  FMS  etiopathogenesis,  premenopausal  women 
were  included  into  the  study.  All  subjects  were 
asked to complete a general questionnaire including 
questions about detailed personal medical history, 
vitamin D usage, age, location, menstruation cycle, 
smoking and alcohol consumption. Participants who 
had neurological, inflammatory, endocrine, chronic 
disease, osteoporosis, pregnancy previously exist-
ing psychiatric illness and taking vitamin D sup-
plementation were excluded from the study. Since 
serum 25-OH vitamin D levels show seasonal varia-
tions and summer sunshine is an important source 
of vitamin D, blood samples were taken from the 
patients in July and August.
Serum 25-OH vitamin D levels were measured 
in Roche E170 hormone analyzer by electrochemi-
luminescence method and results were reported in 
units of ng/ml. 
Descriptive statistical methods (mean, standard 
deviation) were used to evaluate the data. All results 
are expressed as mean plus minus standard devia-
tion and percentage. The unpaired Student’s t test 
was used to evaluate the significance of differences 
between groups. Spearman correlation analysis was 
used to determine the correlations between findings. 
P values less than 0.05 were considered significant, 
at 95%confidence interval. Data were analyzed us-
ing the SPSS/PC statistical software package (SPSS, 
v.20.0 for Windows, SPSS Inc. Chicago).
This study was approved by the ethics commit-
tee of Ataturk University Faculty of Medicine, and 
informed consent was obtained from each subject. N. K. Baygutalp et al. Serum vitamin D levels and clinical findings of fibromyalgia 448
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The procedures followed were in accordance with 
the ethical standards of the responsible committee 
on human experimentation and with the Helsinki 
Declaration of 1975, as revised in 1983.The authors 
declare that there is no conflict of interest.
RESULTS
The mean age of patients was 35±7.45 years for the 
FMS group and 36±8.29 years for the control group. 
There  were  no  significant  differences  between 
groups in terms of age (p>0.05). The mean dura-
tion of symptoms in the FMS group was 4.35±1.20 
years.  The  mean  tender  point  score  in  the  FMS 
group was 15.3±1.8 points.
25-OH vitamin D levels of FMS patients and 
control group are shown in Table 1. Serum 25-OH 
vitamin D levels were significantly lower in patient 
group compared with control group (p=0.04). There 
was no significant correlation between age and 25-
OH vitamin D levels. Mean, standard deviation and 
percentage values of clinical findings are given in 
Table 2.
The  correlations  of  25-OH  vitamin  D  levels 
and  clinical  findings  in  FMS  patients  were  ana-
lyzed (Table 3). There were significantly negative 
correlations between 25-OH vitamin D levels and 
widespread body pain (r=-0.731, p<0.01), Beck de-
pression scores (-0.777, p<0.01), headache (-0.629, 
p<0.01), and sleep disorder (r=-0.767, p<0.01) in 
FMS patients.
Table 1. 25-OH vitamin D levels of FMS patients and the 
control group
FMS group Control group p
25-OH vitamin D
(ng/ml)
13.92±6.19 20.49±7.63 0.04
Table 2. Mean, standard deviation and percentage values 
of clinical findings in FMS patients
Clinical finding Mean ± SD % 
WBP 3.97±2.65
Fatique 2.83±2.45
FIQ 19.27±21.52
NTP 5.95±5.45
Beck DS 23.46±21.22
Morning Stiffness (minutes) 12.36±4.74
Headache 73.70
Sleep Disorder 63.20
SD: Standard deviation, WBP: Widespread Body Pain, 
FIQ: Fibromyalgia Impact Questionnaire, NTP: Number 
of Tender Points, Beck DS: Beck Depression Scores
Table 3. Correlation coefficients (r) of 25-OH vitamin D levels with clinical findings in FMS patients
WBP Fatigue FIQ NTP Beck DS Morning Stiffness Headache Sleep Disorder
25-OH Vitamin D -0.731* 0.196 0.231 -0.250 -0.777* 0.683 -0.629* -0.767*
WBP: Widespread Body Pain, FIQ: Fibromyalgia Impact Questionnaire, NTP: Number of Tender Points, Beck DS: Beck 
Depression Scores, * :p<0.01
DISCUSSION
The main aim of the study is to identify serum 25-
OH vitamin D levels and to investigate the relation-
ship between 25-OH vitamin D and clinical findings 
on  patients  with  fibromyalgia  syndrome  (FMS), 
which is a chronic pain syndrome.
In literature, findings on vitamin D levels in 
FMS patients show varying scores. Many studies 
examining vitamin D levels in FMS patients in dif-
ferent countries of the world have reported low or 
insufficient levels. Low levels have been reported 
in studies which were conducted in Europe [19,20], 
the United States [21], in S. Arabia and Pakistan 
with a high percentage of as 74 % of FMS patients 
[22]. Low levels of vitamin D were also reported 
in a recent study conducted on 141 FMS patients 
in Turkey. Vitamin D deficiency was detected in 76 
% of patients and it was concluded that vitamin D 
treatment in FMS patients might cause regression of 
disease symptoms [23].
On the contrary there are studies which have 
not reported differences in serum levels of vitamin 
D levels between FMS patients and healthy controls 
[24]. Similar with most studies in the literature, in 
our study vitamin D levels in patients with FMS N. K. Baygutalp et al. Serum vitamin D levels and clinical findings of fibromyalgia 449
Dicle Tıp Derg / Dicle Med J    www.diclemedj.org   Cilt / Vol 41, No 3, 446-450
were found to be lower than the level in the control 
group.
The relation of vitamin D deficiency and chron-
ic pain is also focused in literature. In many stud-
ies vitamin D deficiency is pointed to play a role 
in chronic widespread pain syndromes including fi-
bromyalgia [25,26]. Although the basic function of 
vitamin D is to regulate bone metabolism, muscle 
and nervous system are two of the target organs of 
vitamin D [27].
Even though it is not exactly known how vita-
min D deficiency creates pain and how vitamin D 
therapy reduces pain, there is strong evidence for 
abnormal central pain processing in FMS in vitamin 
D insufficiency. There are several theories on how 
vitamin D level affects pain. One of these theories 
suggests that insufficient vitamin D causes impair-
ment on bone metabolism by a series of reactions. 
Insufficient vitamin D levels impair bone mineral-
ization by causing formation of a spongy matrix be-
low the periosteal membrane. This gelatin-like ma-
trix can expand by liquid absorption and can cause 
formation of an outward pressure from periosteum. 
As a result, it causes pain generation in these tis-
sues,  which  are  highly  innerved  by  nerve  fibers 
[28,29].  Another  theory  suggests  that  infections 
activate inflammatory cytokines, which modulates 
central and peripheral pain sensation in FMS [30].
Since 1,25(OH)2 vitamin D takes part in immune 
system regulation, a relationship can be set between 
vitamin D deficiency and muscle pains [31].
In a recent study conducted with a large popu-
lation of 3495 women and 3365 men FMS patients, 
relationship between 25-OH vitamin D levels and 
increased pain level in female patients were report-
ed [31].
On the other hand, in many studies conducted 
with FMS patients, negative correlations were also 
found  between  vitamin  D  levels  and  widespread 
body pain [25], and skeletal pain [26]. In our study, 
negative correlations were found between vitamin 
D levels and widespread body pain and headache in 
FMS patients. Our results point additional evidence 
on the fact that vitamin D deficiency might create 
pain.
Since FMS patients have various symptoms and 
no significant disorder could be found by physical 
examination and laboratory findings, symptoms are 
thought to be psychological. Many studies showed 
negative correlation between 25-OH vitamin D lev-
els and Beck depression scores on FMS patients 
[32,33]. Besides there are many reasons for abnor-
mal pain sensation and other symptoms of FMS pa-
tients, psychological disorders are accepted to have 
a role in improvement of severity of pain sensation.
 Another noteworthy finding of our study is, the 
significant negative correlation (r=-0.777, p<0.01) 
found between vitamin D levels and Beck depres-
sion scores in FMS patients supports the data that 
increased  prevalence  of  depression  might  be  ob-
served in FMS patients. 
In a study determining 25-OH vitamin D levels 
in FMS patients and healthy controls, much sleep 
disturbance was reported to be seen in patients who 
had lower 25-OH vitamin D levels [33]. Similarly, 
a relationship between 25-OH vitamin D levels and 
sleep disturbance was found in our study.
As a result of our study, we determined that 
vitamin D levels are lower in patients with FMS 
than those in control group, and we concluded that 
vitamin D levels are effective on FMS symptoms. 
Since etiopathogenesis of FMS is not well known, 
treatment of FMS should be planned according to 
existence and severity of prominent symptoms.
Small sample size is the limitation of our study. 
Since determination and, if necessary, replacement 
of 25-OH vitamin D levels can play a key role in 
treatment of FMS symptoms; we consider that, re-
lation between 25-OH vitamin D and fibromyalgia 
symptoms should be supported by follow-up stud-
ies conducted in large number of patients, including 
study groups with and without vitamin D supple-
mentation. 
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